Peiminine ameliorates bleomycin-induced acute lung injury in rats

The aim of this study was to investigate whether or not peiminine inhibits lung inflammation and pulmonary fibrosis in a rat model of bleomycin-induced lung injury. Rats were randomly divided into 4 groups. In 3 groups, intratracheal bleomycin (5 mg/kg) was used to induce acute lung injury, followed by administration of either carboxymethyl cellulose (control group, n=14), dexamethasone (DXS group, n=14) or peiminine (peiminine group, n=10). In the fourth group (sham-operated, n=12), normal saline was instilled instead of bleomycin, followed by administration of carboxymethyl cellulose. Drugs were administered intragastrically for 28 days. Lung sections were stained with hematoxylin and eosin (H&E) and Masson's trichrome, to grade the degree of alveolitis and pulmonary fibrosis. The lung index was calculated as the ratio of lung to body weight. Serum levels of interleukin-4 (IL-4), tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) were obtained using a radioimmunoassay. Immunocytochemical methods were employed to assess the expression of transforming growth factor-beta (TGF-beta), connective tissue growth factor (CTGF), NF-kappa B, extracellular signal-related kinase (ERK1/2), Fas and FasL in lung tissue. Peiminine and DXS significantly reduced alveolar inflammation and pulmonary interstitial inflammation in rats with bleomycin-induced lung injury. These protective effects were associated with significant (P<0.05) decreases in the levels of IFN-gamma in serum and of TGF-beta, CTGF, ERK1/2, NF-kappa B and FasL in lung tissue. No effects were observed on serum TNF-alpha or IL-4. In conclusion, peiminine inhibits lung inflammation and pulmonary fibrosis in a rat model of bleomycin-induced lung injury, by reducing circulating IFN-gamma levels and inhibiting signal transduction pathways involving TGF-beta, CTGF, ERK1/2, NF-kappa B and FasL.